So proud of all Charles River Laboratories colleagues that have contributed to leveraging our depth and breadth of institutional knowledge as we progress the development of safe, effective alternatives. Our collaboration with Sanofi to advance the use of Virtual Control Groups is one example of many where we are utilizing technology to advance science
#artificialintelligence#machinelearning#techdriveninnovation#data
Exciting news today! looking forward to this collaboration with Sanofi to explore the use of virtual control groups on non clinical safety studies.
Virtual control groups have the potential to revolutionize drug reaserch by reducing the need for traditional control groups, using advanced data analytics.
This collaboration will leverage the expertise of both teams to develop, qualify and validate virtual control group. We believe that this has the potential to significantly improve the non clinical study process and optimize the development of new treatment for patients.
Charles River Laboratories#virtualcontrolgroups#nonclinical#animalreduction#3rs
So proud of all Charles River Laboratories colleagues that have contributed to leveraging our depth and breadth of institutional knowledge as we progress the development of safe, effective alternatives. Our collaboration with Sanofi to advance the use of Virtual Control Groups is one example of many where we are utilizing technology to advance science
#artificialintelligence#machinelearning#techdriveninnovation#data
Developing new drugs is an immense challenge, with over 90% of these endeavors ending in failure. The inefficiency during the initial stages of drug discovery, notably in animal testing and clinical trials, poses a significant hurdle. How can we enhance efficiency? Dive into this insightful article to discover game-changing technologies poised to transform drug development. ⬇ 🔍
Join Automata's Alice Tome-Fernandez for Technology Networks' free webinar, 'Revolutionizing Drug Discovery: Unleashing the Power of High-Throughput Screening' next Thursday 🧫
Hear from industry experts about how high-throughput screening is transforming medicine discovery.
Don't miss out - register now!
#DrugDiscovery#LabAutomation#Webinar
The future of drug development is taking a leap forward with AI-powered biosimulations.
Verisim Life is revolutionizing the pharmaceutical landscape by replacing traditional animal drug testing with cutting-edge, AI-enabled biosimulation models. These disease-specific simulations replicate real interactions between drugs and biological systems, offering the precision and accuracy that researchers have long pursued. Gone are the days of time-consuming and often unreliable animal testing—an era where technology enhances the success rate of drug candidates is on the horizon.
With such innovations, the speed of drug development stands to increase, ushering in a new era where accurate, efficient, and ethical practices take center stage. In a world where every second counts, leveraging AI in biosimulations is more than just a technological advancement; it’s a pathway to better healthcare outcomes.
#AI#Biosimulation#DrugDevelopment#PharmaInnovation#HealthcareRevolution
Visit https://workflo.agency for your edge in automation. Discover how automation can streamline your business processes and set you apart from the competition. Don't miss out on the future—schedule your free consultation today.
It's exciting to have partners who align with our mission of removing regulatory friction in order to accelerate the time it takes to get drugs to patients who need them. I love how Joel highlights the key problems we're solving here at Weave:
"Yet, given how manual and labor-intensive the effort is, necessitating the collaborative efforts of large, multidisciplinary teams, most companies wait until the very last experimental data comes in before sprinting for months to summarize years of work in a single document. This is inefficient and can create costly errors that result in clinical holds that slows the drug from impacting patient care."
This is just the beginning. Stay tuned for more as we continue to build out our first product, AutoIND.
We are thrilled to announce our lead investment in Weave Bio, a groundbreaking company poised to transform the regulatory reporting landscape in drug development. We are proud to partner with the entire Weave Bio team — including Ari Caroline, Umut Eser, Brandon Rice, and Lindsay Mateo, MBA.
The Weave team bridges life #science, regulatory, #AI, and software expertise for this exciting journey. The road ahead is long, but the potential impact on patient care and the #drugdevelopment process is immense.
https://lnkd.in/d9BY_mBn
Niven Narain, CEO of BPGbio and a member of the Forbes Technology Council, recently shared his insights on the expanding, yet overhyped, role of AI in the drug discovery sector. From the outset, Niven has consistently championed a methodology that is now being echoed in the discourse at the recent JPM conference, as the dust begins to settle. 'AI revolutionizes drug development by boosting efficiency, improving data analysis, and reshaping trial structures. This addresses the escalating costs and high failure rates in drug development. A biology-first AI approach enhances patient specificity, enabling quicker identification of viable candidates for clinical trials and fostering faster success.' #DrugDiscovery#ArtificialIntelligence#PrecisionMedicine#Biotech#PharmaInnovation #ClinicalTrials#PersonalizedMedicine #HealthTech#InnovationInHealthcare#ForbesTechnologyCouncil
It was an honor to participate in the insightful "Artificial Intelligence in Drug Development" event. A big thank you to Leon 'Jun' T. and Shijing (Nora) Luo, for hosting such a fantastic event. The panel discussion delved into AI’s transformative role in drug development, with expert contributions from Alexandra Snyder, MD, Lipeng Lai, and Lily Zhang, each sharing unique perspectives on AI's profound impact on the pharmaceutical industry. Kudos to the InScienceWeTrust Community, SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia), and BioSpark Group for organizing this event!
During the event, our Co-Founder and CEO, Sharon Chen, highlighted how GenAI-powered solutions are set to revolutionize clinical development by optimizing both data management and medical writing across every stage. Some key takeaways from Sharon's sharing:
According to a recent McKinsey report, GenAI has the potential to generate $13 to $25 billion annually in clinical development, creating substantial value for the industry. At AlphaLife Sciences, we build end-to-end, intelligent, modular solutions tailored to the unmet needs of sponsors and CROs. These highly adaptable solutions enhance clinical trial efficiency. Our offerings include:
* GenAI-Copiloted Medical Writing Solutions: These solutions accelerate document creation while improving process efficiency, quality, and data consistency. Key applications include CSR writing, patient safety narratives, protocol writing, protocol design, and more.
* GenAI-Powered Data Management Solutions: These solutions streamline data management, improve decision-making, ensure data integrity, and support regulatory compliance. Key applications include EDC, data monitoring, and more.
At AlphaLife Sciences, we believe that GenAI transcends process efficiency—it unlocks insight efficiency and concept efficiency, empowering AI to extract transformative insights that drive innovation in clinical development.
For more information, visit https://lnkd.in/epRVtrve#ArtificialIntelligence#MedicalWriting#DataManagement#ClinicalTrials#AlphaLifeSciences#GenAI#AlphaLifeSciences#clinicalresearch#GenAIsoftware#GenAISolution
https://lnkd.in/eJMbkuU4
⏰⏰⏰ Our popular #BioverseWebinar Ep 12 #ArtificialIntelligenceInDrugDevelopment is now on YouTube! Thank you, Alexandra Snyder, MD from Generate:Biomedicines, Lily Zhang from Jones Day, Sharon Chen from AlphaLife Sciences, and Lipeng Lai from XtalPi Inc., for a 90-minute worth of great insights!
The panel discussion on AI's role in drug development showcased the diverse expertise of each speaker. Below are some highlights from the 90-minute webinar.
Alexandra Snyder, MD highlighted AI's potential in #BiologicsDrugDiscovery, focusing on designing antibodies with non-immunogenic targets and optimizing multiple attributes simultaneously. She also discussed the importance of collaboration and raised concerns about the ethical and social implications of AI, particularly its "black box" nature in a highly regulated environment.
Lily Zhang emphasized the significance of #IPProtection, exploring the legal and ethical challenges in AI-driven drug development. She addressed the complexities of patenting AI-generated innovations and the advantages and limitations of #Copyrights, #Patents, and #TradeSecrets in this context.
Sharon Chen concentrated on AI's impact on #ClinicalDevelopment, advocating for the use of AI to streamline processes and improve #DataManagement. She also touched on collaboration, stressing the need for AI to work within a broader ecosystem to maximize its potential in drug development.
Lipeng Lai focused on AI's applications in both #SmallMolecule and #Biologics drug development, detailing AI's success in #MolecularDesign, #ClinicalDataAnalysis, and #MarketStrategies. He also emphasized the importance of collaborations, particularly between AI companies and big pharma, to enhance efficiency and reduce costs.
Each speaker provided unique insights, reflecting their areas of expertise and the multifaceted role of AI in the pharmaceutical industry.
Scientific Director @ Tecniplast | Neuropharmacology PhD | 1st Cialdini Certified Professional in Germany and Italy | Keynote Speaker
3moThat is a great achievement. Charles River Laboratories also contributed not only in safety and toxic space but also, more generally, to the repurpose (use of historical data) concept in all animal research: https://www.nature.com/articles/s41684-024-01335-0 with Gunnar Flik.